open access

Vol 78, No 11 (2007)
ARTICLES
Get Citation

Maternal serum concentration of placental growth factor (PlGF) and endothelial growth factor (VEGF) in pregnancies complicated by preeclampsia

Anna Semczuk-Sikora, Arkadiusz Krzyżanowski, Maciej Kwiatek, Marian Semczuk
Ginekol Pol 2007;78(11).

open access

Vol 78, No 11 (2007)
ARTICLES

Abstract

Preeclampsia is one of the most frequent and dangerous complications of a pregnancy. In preeclamptic pregnancies the spiral arteries are not modified properly. Disturbed blood flow finally leads to hypoxia which is responsible for the dysfunction of the endothelium. Endothelial growth factor (VEGF) and placental growth factor (PIGF) play an important role in the angiogenesis and thus may participate in the pathomechanism of preeclampsia. Aim: The aim of our study was to estimate VEGF and PIGF level in serum of patients with preeclampsia. Materials and methods: The study comprised 25 gravidas with preeclampsia and a control group of 18 healthy gravidas. In 25 preeclamptic women the angiogenic factors levels were measured in the III trimester and in 7 of them in the II trimester. In the control group these parameters were assessed in both periods. Both factors were measured by commercial available ELISA KIT. Results: PIGF concentrations were significantly (p<0,001) lower in sera of patients with preeclampsia in the II and III trimester in comparison to the controls: 17,4 vs. 290,3pg/ml and 99,1 vs. 347,8pg/ml, respectively. In most cases serum VEGF levels were undetectable. Conclusions: 1. PIGF is involved in the pathomechanism of preeclampsia and its maternal serum concentration decreases significantly in the course of the disease. 2. The sensitivity of the commercially available ELISA assay is too low to assess the serum VEGF concentration in women with preeclampsia.

Abstract

Preeclampsia is one of the most frequent and dangerous complications of a pregnancy. In preeclamptic pregnancies the spiral arteries are not modified properly. Disturbed blood flow finally leads to hypoxia which is responsible for the dysfunction of the endothelium. Endothelial growth factor (VEGF) and placental growth factor (PIGF) play an important role in the angiogenesis and thus may participate in the pathomechanism of preeclampsia. Aim: The aim of our study was to estimate VEGF and PIGF level in serum of patients with preeclampsia. Materials and methods: The study comprised 25 gravidas with preeclampsia and a control group of 18 healthy gravidas. In 25 preeclamptic women the angiogenic factors levels were measured in the III trimester and in 7 of them in the II trimester. In the control group these parameters were assessed in both periods. Both factors were measured by commercial available ELISA KIT. Results: PIGF concentrations were significantly (p<0,001) lower in sera of patients with preeclampsia in the II and III trimester in comparison to the controls: 17,4 vs. 290,3pg/ml and 99,1 vs. 347,8pg/ml, respectively. In most cases serum VEGF levels were undetectable. Conclusions: 1. PIGF is involved in the pathomechanism of preeclampsia and its maternal serum concentration decreases significantly in the course of the disease. 2. The sensitivity of the commercially available ELISA assay is too low to assess the serum VEGF concentration in women with preeclampsia.
Get Citation

Keywords

PIGF, VEGF, preeclampsia, pregnancy, Blood

About this article
Title

Maternal serum concentration of placental growth factor (PlGF) and endothelial growth factor (VEGF) in pregnancies complicated by preeclampsia

Journal

Ginekologia Polska

Issue

Vol 78, No 11 (2007)

Bibliographic record

Ginekol Pol 2007;78(11).

Keywords

PIGF
VEGF
preeclampsia
pregnancy
Blood

Authors

Anna Semczuk-Sikora
Arkadiusz Krzyżanowski
Maciej Kwiatek
Marian Semczuk

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl